Replies to post #277429 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

I doubt it. But...

Seriously...has other biotech companies scheduled a conference at a CTAD Alzheimer conference to release the results of their phase 2 trial from another disease unrelated to Alzheimers?

Good question. I doubt that it has happened.

The bigger question is, why, ever, would the people running this conference allow this to happen, to allow the revelation of detailed clinical results for a different, somewhat unrelated disease? How was this arranged, by whom, for what purpose?

Clearly, Anavex people had to approach the CTAD people and convince them that their presentation of the Parkinson's disease dementia results were both significant, and more importantly, applicable and useful for Alzheimer's researchers.

"Dr. Missling, thank you for your call, but we are the CLINICAL TRIALS ON ALZHEIMER'S DISEASE people. You will need to go to the Parkinson's people. We don't do Parkinson's stuff. Very different disease."

Dr. Missling, "But sir, take a look at these data. See how our drug really therapeutically nailed the dementia of Parkinson's. Blarcamesine can do that for Alzheimer's, too. Your people need to know about this, see the data."

The CTAD guy, "Whoa! Look at those metrics. Stat sig through and through. Yes, our people need to learn of this. It will be our honor to roll out these data for the whole world, for everybody dealing with CNS pathologies involving loss of cognition and consequent dementia."

[Steady_T]

In this case I think the Alzheimer's conference people know that there are AD trials underway for 2-73. They have seen the data from P2a/b & OLE so they know there is potential that has been strongly hinted at but no controlled trial results.

Now the company has controlled trial results that demonstrate/confirm the MOA of 2-73. This confirmation has direct support for the ongoing AD P3 trial.

So that is why the AD conference would be interested in hearing about the Anavex 2-73 results in a controlled PDD trial.

As has been pointed out before, the MOA of 2-73 is a paradigm shift and that includes AD. The PDD results confirm the paradigm shift.

[attilathehunt]

(PD)Dementia is related to Alzheimers

From ALZ.org...

Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Alzheimer’s is the most common cause of dementia. Alzheimer’s is a specific disease. Dementia is not.